

Contents

Contributors	xiii
Preface	
Ralph Reisfeld and Stewart Sell	xxi
I. MONOCLONAL ANTIBODIES TO HUMAN CANCER	
Cancer Markers: Past, Present and Future	
Stewart Sell	3
Comparisons of Qualitative and Quantitative Immunoassays for <i>ras</i> p21	
P. Horan Hand, A. Thor, A. Caruso, D. Wunderlich, R. Muraro, M.O. Weeks, V. Vilasi, and J. Schlom	23
Clinical Application of Monoclonal Antibodies Reactive With Epithelial Ovarian Cancer	
Robert C. Bast, Jr., Vincent R. Zurawski, Jr., and Robert C. Knapp	37
Monoclonal Antibodies Directed Against Lymphomas of the Monocyte/Reticulum Cell System	
Su-Ming Hsu, Mark D. Pescovitz, and Pei-Ling Hsu.	53
DU-PAN-2: A Pancreatic Adenocarcinoma Associated Antigen	
Richard S. Metzgar, David M. Mahvi, Michael J. Borowitz, Michael S. Lan, William C. Meyers, H.F. Seigler, and Olivera J. Finn	63
II. HUMAN-HUMAN HYBRIDOMAS	
The EBV-Hybridoma Technique and Its Application to Human Lung Cancer	
S.P.C. Cole, D. Kozbor, and J.C. Roder	77
Human Monoclonal Antibodies to Human Cancer Cells	
Mark C. Glassy, S.A. Gaffar, Robert E. Peters, and Ivor Royston ..	97
III. MONOCLONAL ANTIBODY THERAPY IN PATIENTS WITH LEUKEMIA AND LYMPHOMA	
Treatment of Relapsed Non-Hodgkin's Lymphoma Utilizing Purged Autologous Bone Marrow	
Tak Takvorian, Kenneth C. Anderson, Jerome Ritz, and Lee M. Nadler.	113
Observations on the <i>In Vivo</i> Fate of Cells Coated with Murine Monoclonal Antibodies	
Paul J. Martin, Cliff Astley, Albert Giorgio, Barbara Weiblen, C. Robert Valeri, and John A. Hansen.	121

Clinical Trial of 24 Hour Infusions of T101 Murine Monoclonal Antibody

- Robert O. Dillman, Jacquelyn Beauregard, Daniel L. Shawler,
Maurie Markman, Samuel E. Halpern, Maureen Clutter, and
Kevin P. Ryan 133

IV. MODULATION OF EFFECTOR CELLS BY MONOCLONAL ANTIBODIES

Antibody-Dependent Cellular Cytotoxicity to Human Melanoma Antigens

- Karl Erik Hellström, Ingegerd Hellström, Gary E. Goodman, and
Vera Brankovan 149

Destruction of Human Tumors by IgG2a Monoclonal Antibodies and Macrophages

- Dorothee Herlyn, Michael Lubeck, Zenon Steplewski, and
Hilary Koprowski 165

Approaches for Immunotherapy of Malignant Melanoma With Monoclonal Antibodies

- Ralph A. Reisfeld, Gregor Schulz, and David A. Cheresch 173

Antibody-Dependent Cellular Cytotoxicity (ADCC) Against Human Melanoma by Human Effector Cells in Cooperation With Mouse Monoclonal Antibodies

- Ronald B. Herberman, A. Charles Morgan, Ralph Reisfeld,
David A. Cheresch, and John R. Ortaldo 193

V. DRUG-ANTIBODY CONJUGATES

Effect of Monoclonal Antibody-Drug Conjugates on the *In Vivo* Growth of Human Tumors Established in Nude Mice

- Nissi M. Varki, Ralph A. Reisfeld, and Leslie E. Walker 207

Design and Therapeutic Evaluation of Monoclonal Antibody 791T/36-Methotrexate Conjugates

- Robert W. Baldwin, Lindy Durrant, M.J. Embleton, M. Garnett,
M.V. Pimm, R.A. Robins, J.D. Hardcastle, N. Armitage, and
K. Ballantyne 215

Localization and Biodistribution Studies of a Monoclonal Antibody in Patients With Melanoma

- P.G. Abrams, A.C. Morgan, R.W. Schroff, C.S. Woodhouse,
J. Carrasquillo, H.C. Stevenson, M.F. Fer, R.K. Oldham, and
K.A. Foon 233

Parameters Affecting the Utility of Monoclonal Antibodies as Carriers of Drugs, Toxins and Radioisotopes

- Alton C. Morgan, Jr., Robert W. Schroff, John W. Pearson, and
Gowsala Pavanadasivam 237

Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy

- Ruth Arnon, Bilha Schechter, and Meir Wilchek 243

Workshop Summary: Monoclonal Antibody Conjugates With Drugs or Toxins

- Thomas F. Bumol 257

VI. TOXIN-ANTIBODY CONJUGATES

- Potiation of Cytotoxicity Induced by Immunotoxins**
 Pierre Casellas, Hildur E. Blythman, Bernhard J.P. Bourrié,
 X. Canat, Dominique Carrière, Guy Laurent and F.K. Jansen 263
- Inhibition of Human Peripheral Blood T-Cells by Immunotoxins
 Containing Pokeweed Antiviral Protein**
 S. Ramakrishnan, F.M. Uckun, and L.L. Houston 275

VII. MONOCLONAL ANTIBODIES TO CELL SURFACE RECEPTORS

- Production of Probes for the Study of Cell Receptors Using
 Idiotype-Anti-Idiotype Molecular Mimicry**
 D. Scott Linthicum and Michael B. Bolger 289
- Anti-Thyrotropin-Anti-Idiotypes as Probes for Thyrotropin
 Receptor Structure and Function**
 Nadir R. Farid 299
- Immune Responses Directed to Monoclonal Immunoglobulins on
 Malignant B Cells**
 Richard G. Lynch 317
- A Search for "Internal Image" Anti-Idiotypic Antibodies:
 A Subpopulation of Anti-f Met-Leu-Phe Anti-Idiotypic Antibodies
 Binds to the Formyl Peptide Chemotaxis Receptor of the
 Neutrophil and to Several Genetically Unrelated Anti-f Met-Leu-
 Phe Antibodies**
 Wayne A. Marasco, Jerome Charles, and Peter A. Ward 327
- Idiotypic Routes to Monoclonal Anti-Receptor Antibodies**
 W.L. Cleveland, N.H. Wasserman, A.S. Penn, H.H. Ku, B.L. Hill,
 R. Sarangarajan, and B.F. Erlanger 345
- Biochemical Characterization of a Prostate Tissue Antigen**
 Ann M. Carroll and Mark I. Greene 359
- Use of Monoclonal Anti-Idiotypic Antibodies as Specific Vaccines
 and as Probes of the Mammalian Reovirus Type 3 Receptor**
 Glen N. Gaulton, Man Sung Co, and Mark I. Greene 367

VIII. MONOCLONAL ANTIBODIES TO LYMPHOKINES

- Monoclonal Antibodies to Human IL-2 and the IL-2 Receptor**
 Christopher S. Henney, Steven Gillis, Steven K. Dower, and
 David L. Urdal 383
- Applications of Monoclonal Antibodies to Investigations of Growth
 Factors, Their Receptors and Tumor Antigens, and an Adjuvant
 Formulation Potentially Useful for Immunization Against
 Malignant Diseases**
 Anthony C. Allison and Alain B. Schreiber 397
- Characterization of a Monoclonal Antibody to CSF-2 α (IL-3)**
 P.J. Conlon, H. Luk, L. Park, T. Hopp, and D. Urdal 413
- Regulatory Issues Surrounding Therapeutic Use of Monoclonal
 Antibodies: Points to Consider in the Manufacture of Injectable
 Products Intended for Human Use**
 Thomas Hoffman, James Kenimer, and Kathryn E. Stein 431

IX. MONOCLONAL ANTIBODY-RADIONUCLIDE CONJUGATES

Biochemical Effects and Cancer Therapeutic Potential of Tunicamycin	
Kenneth Olden, Martin J. Humphries, and Sandra L. White	443
Use of Monoclonal Antibodies for Detection of Lymph Node Metastases	
John N. Weinstein, Christopher D.V. Black, Andrew M. Keenan, Oscar D. Holton, III, Steven M. Larson, Susan M. Sieber, David G. Covell, Jorge Carrasquillo, Jacques Barbet, and Robert J. Parker	473
Workshop Summary: Monoclonal Antibodies to Extracellular Matrix and Cytoskeletal Components	
Michael D. Pierschbacher	489

X. CANCER VACCINES

Applications of Monoclonal Antibodies to Active Specific Immunotherapy	
Malcolm S. Mitchell	495
Human Monoclonal Antibodies: Generation of Tumor Cell Reactive Monoclonal Antibodies Using Peripheral Blood Lymphocytes From Actively Immunized Colorectal Carcinoma Patients	
Martin V. Haspel, Richard P. McCabe, Nicholas Pomato, Herbert C. Hoover, Jr., and Michael G. Hanna, Jr.	505
Monoclonal Antibodies in the Development of Active Specific Immunotherapy for Melanoma	
June Kan-Mitchell, Raymond A. Kempf, Ashraf Imam, Ralph A. Reisfeld, and Malcolm S. Mitchell	523
Approaches to Augmenting the Immunogenicity of Tumor Antigens	
Philip O. Livingston, L.J. Old, and H.F. Oettgen	537

XI. MONOCLONAL ANTIBODIES TO ONCOGENE PRODUCTS

Use of Monoclonal Antibodies to Probe the Functional Activity of the Cellular <i>src</i> Gene Product in Polyoma Virus Transformed Cells	
Wes Yonemoto, Joseph Bolen, Mark Israel, Leah Lipsich, and Joan S. Brugge	551
A Monoclonal Antibody Raised Against a ras Related Synthetic Peptide Shows Immunoreactivity With Human Carcinomas	
Walter P. Carney, H.J. Wolfe, D. Petit, L. Bator, R. DeLellis, A.S. Tischler, Y. Dayal, P. Hamer, G. Cooper, and H. Rabin.	565
Biologic Considerations for the Development of Animal Models to Study Treatment of Metastatic Human Neoplasms	
Isaiah J. Fidler and Raffaella Giavazzi.	573
Index	587